Skip to main content

MINI REVIEW article

Front. Bioeng. Biotechnol.
Sec. Nanobiotechnology
Volume 12 - 2024 | doi: 10.3389/fbioe.2024.1474711

Prussian Blue Nanotechnology in the Treatment of Spinal Cord Injury: Application and Challenges

Provisionally accepted
Xiaopeng Gu Xiaopeng Gu 1*Songou Zhang Songou Zhang 1Weihu Ma Weihu Ma 2*
  • 1 School of Medicine, Ningbo University, Ningbo, China
  • 2 Ningbo No.6 Hospital, Ningbo, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Spinal cord injury (SCI) is a serious neurological condition that currently lacks effective treatments, placing a heavy burden on both patients and society. Prussian blue nanoparticles exhibit great potential for treating spinal cord injuries due to their excellent physicochemical properties and biocompatibility. These nanoparticles have strong anti-inflammatory and antioxidant capabilities, effectively scavenge free radicals, and reduce oxidative stress damage to cells. Prussian blue nanotechnology shows broad application potential in drug delivery, bioimaging, cancer therapy, anti-inflammatory and oxidative stress treatment, and biosensors. This article reviewed the potential applications of Prussian blue nanotechnology in treating spinal cord injuries, explored the challenges and solutions associated with its application, and discussed the future prospects of this technology in SCI treatment.

    Keywords: spinal cord injury, Prussian Blue Nanotechnology, Treatment, Inflammation, Oxidative Stress

    Received: 05 Aug 2024; Accepted: 28 Aug 2024.

    Copyright: © 2024 Gu, Zhang and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaopeng Gu, School of Medicine, Ningbo University, Ningbo, China
    Weihu Ma, Ningbo No.6 Hospital, Ningbo, Zhejiang Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.